Please Wait...

CREAT // Creatinine

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Produced by muscle metabolism, creatinine is a degradation product of creatine phosphate and is essentially eliminated through the kidneys (Onuigbo and Agbasi, 2015). Creatinine metabolism is constant in one person and, in non-pathological situation, has a production rate equivalent to the renal extraction rate. Its concentration in serum is then dependent of the elimination capacity of the kidneys. Serum creatinine is the oldest and the most commonly used marker for estimating the glomerular filtration rate (Perrone et al., 1992). In order to minimize variation induced by liquid intake, numerous urinary biomarkers are normalized with the creatinine value in urine.

Bioclinica Lab employs an automated colorimetric assay based on the Jaffé method for the measurement of Creatinine in serum or in urine.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

With many clinical trials slowed or terminated, investments in new technologies are difficult. Yet, a #CTMS with a… https://t.co/VRIhWWf4tE
Bioclinica (2 weeks ago)
With Bioclinica #CTMS, sponsors & CROs have access to a full-featured, scalable system - a single, centralized sour… https://t.co/7ACrv8cvuF
Bioclinica (2 weeks ago)
Now available: a DIY #EDC solution. From study start-up to close-out, Bioclinica EDC Solo is an efficient, cost-eff… https://t.co/vFhC7ITfZV
Bioclinica (3 weeks ago)
Reduce the number of user requirement iterations and UAT findings during the #IRT build process. With the agile app… https://t.co/TJt2sZlrFP
Bioclinica (3 weeks ago)
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin… https://t.co/qIpi1MESXw
Bioclinica (4 weeks ago)
According to our recent poll, 45% of respondents had neither a #CTMS nor an #eTMF system, while only 24% had both.… https://t.co/l4dKC7pBQo
Bioclinica (4 weeks ago)